Evidence map›Paper›PMID 34861842›Full record

ReviewPediatric rheumatology online journal2021

A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report.

Margaux Boistault, Mireia Lopez Corbeto, Pierre Quartier, Laura Berbel Arcobé, Ariadna Carsi Durall, Florence A Aeschlimann

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Pediatric rheumatology online journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Polyarteritis Nodosa: Old Disease, New Etiologies.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Margaux Boistault *Department of Pediatric Immunology-Hematology and Rheumatology, Necker University Hospital - Assitance Publique-Hopitaux de Paris, Enfants Malades,149, rue de Sèvres, 75015, Paris, France.
Mireia Lopez Corbeto *Pediatric Rheumatology Unit, Vall d'Hebron Hospital Campus, Barcelona, Spain.
Pierre QuartierDepartment of Pediatric Immunology-Hematology and Rheumatology, Necker University Hospital - Assitance Publique-Hopitaux de Paris, Enfants Malades,149, rue de Sèvres, 75015, Paris, France. pierre.quartier@aphp.fr.ORCID http://orcid.org/0000-0002-1769-549X
Laura Berbel ArcobéRheumatology Department, Mútua de Terrassa University Hospital, Terrassa, Barcelona, Spain.
Ariadna Carsi Durall *Pediatric Hospitalisation Unit, Vall d'Hebron Hospital Campus, Barcelona, Spain.
Florence A Aeschlimann *Department of Pediatric Immunology-Hematology and Rheumatology, Necker University Hospital - Assitance Publique-Hopitaux de Paris, Enfants Malades,149, rue de Sèvres, 75015, Paris, France.
Hôpital Necker-Enfants Malades · FRVall d'Hebron Hospital Universitari · ESHospital Terrassa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildhood Polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation of medium- and small-sized arteries. Disease evolution may be severe and refractory to standard treatment including prednisone, azathioprine and cyclophosphamide. CASE PRESENTATION: We present the case of a young girl with severe PAN resulting in progressive ischemia and necrosis of fingers and toes. Biological work-up revealed increased acute phase reactants and interleukin-6 levels. She was only partially controlled despite high-dose corticosteroids and cyclophosphamide infusions, and eventually achieved rapid improvement and sustained remission on tocilizumab. Further, we review the current evidence of the interleukin-6-inhibitor tocilizumab for the treatment of PAN.

conclusionTocilizumab may be an efficient therapeutic option in a subset of treatment-refractory children with PAN.

Indexed as

Antibodies, Monoclonal, HumanizedChild, PreschoolFemaleFootHandHumansPolyarteritis NodosaAntibodies, Monoclonal, HumanizedtocilizumabChildPolyarteritis nodosaTocilizumab

Identifiers

PMID34861842
PMCPMC8641167
OpenAlexW3217784003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.